Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma A/S reported a proposed sale of 10,800 ordinary shares via Citigroup Global Markets on 03/02/2026. The filing also shows 18,349 restricted shares vesting on 03/02/2026 as compensation, and discloses 10,000 shares sold on 12/02/2025 for $2,058,454.18.
Ascendis Pharma A/S reports that the U.S. FDA has granted Accelerated Approval to YUVIWEL (navepegritide; TransCon CNP), the first and only once-weekly treatment to increase linear growth in children 2 years and older with achondroplasia and open epiphyses. YUVIWEL is a prodrug of C‑type natriuretic peptide designed to provide continuous systemic exposure over the weekly dosing interval.
The approval is based on improved annualized growth velocity and is subject to confirmation of clinical benefit in ongoing or future trials. Ascendis plans to make YUVIWEL available in the United States in the early part of the second quarter of 2026 and to support patients through its Ascendis Signature Access Program with treatment navigation and financial assistance services.
With this decision, the FDA also issued Ascendis a Rare Pediatric Disease Priority Review Voucher, which can grant priority review to a future drug application and reflects the rare pediatric nature of achondroplasia.
Ascendis Pharma A/S furnished a Form 6-K providing notice of its March 23, 2026 annual general meeting and attaching its audited 2025 annual report and sustainability report. For 2025, revenue rose to €720.1 million, while the consolidated loss was €228.0 million, which the board proposes to carry forward.
Operating loss improved to €136.3 million, net finance expenses were €92.7 million, and cash and cash equivalents reached €616.0 million with total assets of €1.30 billion. The company reports continued commercial growth of YORVIPATH and SKYTROFA, advances in its TransCon pipeline in endocrinology and oncology, and new strategic collaborations, including a major TransCon semaglutide partnership with Novo Nordisk and regional deals with Teijin, VISEN and Eyconis.
Ascendis Pharma A/S reported strong growth for Q4 and full-year 2025, driven mainly by its endocrine products YORVIPATH and SKYTROFA. Q4 2025 product revenue was €240 million, and full-year 2025 product revenue reached €684 million. Total revenue for 2025 was €720 million, up from €364 million in 2024.
The company generated a Q4 2025 operating profit of €10 million and operating cash flow from operating activities of €73 million, but still posted a full-year net loss of €228 million, improved from a €378 million loss in 2024. Cash and cash equivalents were €616 million as of December 31, 2025. TransCon CNP is under FDA Priority Review with a PDUFA action goal date of February 28, 2026, and management aspires to about €500 million in operating cash flow in 2026 and at least €5 billion in global annual product revenue by 2030.
Ascendis Pharma A/S files its annual Form 20-F, highlighting continued investment-led losses and a growing commercial footprint in endocrinology and oncology. The company markets once-weekly growth hormone SKYTROFA and hypoparathyroidism therapy YORVIPATH in the U.S. and Europe, and is advancing additional TransCon-based candidates.
Ascendis reported a net loss of €228 million for 2025, versus €378.1 million for 2024, and a total equity deficit of €162.8 million at December 31, 2025. Cash and cash equivalents totaled €616 million, which management believes can fund operations for at least twelve months. As of December 31, 2025, there were 61,977,408 ordinary shares outstanding, including ADSs held by the company and subsidiaries.
The filing emphasizes heavy reliance on TransCon technologies, significant ongoing R&D and commercialization spending, potential need for additional financing, and extensive risk factors ranging from intense competition and regulatory uncertainty to manufacturing, reimbursement, cybersecurity, geopolitical and macroeconomic pressures.
Ascendis Pharma A/S received an amended ownership report showing that Westfield Capital Management Company, L.P. beneficially owns 5,185,696 shares of Ascendis common stock, representing 8.48% of the class as of 12/31/2025.
Westfield has sole power to vote 4,244,766 shares and sole power to dispose of 5,185,696 shares. The shares are owned of record by Westfield’s investment advisory clients, who receive dividends and sale proceeds. Westfield states the holdings are in the ordinary course of business and not for influencing control.
Ascendis Pharma A/S reports that its board granted an aggregate of 16,570 warrants to certain employees on February 10, 2026 under Appendix 1a of its Articles of Association. Each warrant allows the holder to subscribe for one ordinary share at an exercise price of US $224.19 per share, matching the closing price of the company’s ADS on the grant date.
Vesting is service-based, with 25% of the warrants vesting on the one-year anniversary of the grant and the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service and possible earlier vesting upon certain exit events. After this grant, warrants to subscribe for an additional 1,666,633 shares remain available for future grants under the Articles of Association.
Artisan Partners has disclosed a significant institutional stake in Ascendis Pharma A/S. Through several affiliated entities, it reports beneficial ownership of 3,225,885 American Depositary Shares, representing 5.2% of the class, based on 61,977,408 shares outstanding as of 12/30/2025.
Artisan Partners has shared voting power over 2,883,433 shares and shared dispositive power over 3,225,885 shares. The shares are held on behalf of discretionary clients of Artisan Partners Limited Partnership, which receive dividends and sale proceeds. The filing states the holdings are in the ordinary course of business and not for changing or influencing control of Ascendis Pharma.
Ascendis Pharma A/S reports that its board granted 42,030 new warrants to certain employees on 13 January 2026 under Appendix 1a of its Articles of Association. Each warrant gives the right to buy one ordinary share at an exercise price of US $215.05 per share, matching the closing price of the company’s ADSs on the grant date.
These warrants vest over time: 25% after one year, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service and possible earlier vesting upon specified exit events. After this grant, warrants to subscribe for an additional 1,683,203 shares remain available for future grants under the Articles of Association, which have been amended to reflect the new issuance.